Research programme: hepatocyte growth factor kringle fragments - Kringle Pharma

Drug Profile

Research programme: hepatocyte growth factor kringle fragments - Kringle Pharma

Alternative Names: NK4; NK4 antitumour protein - Kingle Pharma

Latest Information Update: 12 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kringle Pharma
  • Developer Biolex
  • Class
  • Mechanism of Action Angiogenesis inhibitors; Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 12 Apr 2018 NK4 is still in preclinical trials for Cancer in Japan (Kringle Pharma pipeline, April 2018)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top